“Given the dearth of successful clinical research options in PAD, these study results are exciting,” said study presenter William Hiatt, MD, professor of cardiovascular research in the Department of Medicine, University of Colorado School of Medicine; President of CPC Clinical Research and chairman of the American Heart Association’s Peripheral Vascular Disease Council.

“This non-dilutive award will advance our clinical program and aid us in our mission to introduce approved novel and effective therapies as quickly as possible, providing new hope for patients with PAD, cancer and other conditions related to hypoxia,” said David G. Kalergis, CEO, Diffusion Pharmaceuticals.”

CHARLOTTESVILLE, VA –August 2, 2010 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled “Bipolar Trans Carotenoid Salts and Their Uses.” This patent includes drug formulation and use claims relating to Diffusion’s entire family of first-in-class new chemical entities. [...]

Charlottesville, VA — March 22, 2010 —Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced its selection as the winner of the Perfect Pitch Competition – Biotech Investment Challenge. The winner was announced during a special awards ceremony attended by over 150 delegates and [...]